Press releases
- Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
- Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
- Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
- Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
- Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
- Charles River Laboratories to Present at William Blair and Jefferies Conferences
- Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
- Charles River Laboratories Announces First-Quarter 2024 Results
- Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
- Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
More ▼
Key statistics
As of last trade, Charles River Laboratories International Inc (RV6:FRA) traded at 186.95, 21.04% above the 52 week low of 154.45 set on Oct 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 186.95 |
---|---|
High | 186.95 |
Low | 186.95 |
Bid | 186.25 |
Offer | 187.35 |
Previous close | 188.65 |
Average volume | 11.89 |
---|---|
Shares outstanding | 51.51m |
Free float | 51.00m |
P/E (TTM) | 23.64 |
Market cap | 10.38bn USD |
EPS (TTM) | 8.52 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 07:03 BST.
More ▼